Asia Pacific Osteoarthritis Therapy Market to 2030 - By Size, Share, Growth by End User and Forecast

The Asia Pacific osteoarthritis therapy market was valued at US$ 3,707.81 million in 2022 and is expected to reach US$ 7,037.00 million by 2030; it is estimated to register a CAGR of 8.3% from 2022 to 2030.

Innovative Therapy Options Reducing Dependency on Medications Boost Asia Pacific Osteoarthritis Therapy Market

The non-pharmacologic therapy is a key facet of treating OA. With lifestyle changes and medicines, patients suffering from OA may benefit from various supportive therapy options, including hot or cold packs and assistive devices. Additionally, complementary, and alternative therapy options such as nutritional supplements and rubefacients may help in managing OA. Further, topical treatments, supervised exercises, neuromuscular training, self-management, patient education, and weight loss intervention are among the best treatments suited for OA.

In osteoarthritis knee pain (OKP) treatment, knee braces are used to reduce knee pain as these braces may apply compression (pressure) to soft tissues, stabilize the knee, and redistribute weight. A few examples of knee braces are compression sleeves, hinged knee braces, and unloader knee braces. Also, these compression braces are easily available at drugstores, pharmacies, and online channels. Therefore, availability of innovative therapy options reduces dependency on medications, which drives the osteoarthritis therapy market growth.

Asia Pacific Osteoarthritis Therapy Market Overview

Asia Pacific osteoarthritis therapy market is segmented as China, Japan, India, Australia, South Korea, and Rest of Asia Pacific countries. The patients availability for conducting clinical trials to test drugs intended for osteoarthritis is the most influential factors responsible for market growth during the forecast period. Also, government support for conducting the patient's clinical trials further enhances the market growth during the coming years. According to the Frontiers S.A. report, with China having a high burden of an aging population, knee O.A. is the leading cause of disability, having a burden of huge healthcare costs among the Chinese population. Additionally, the National Institute of Health (NIH) reports that in rural China, symptomatic knee O.A. is more prevalent (16.57%), and this incidence has increased significantly among the population aged 70 years and older (29.25% among women and 24.71% among men). Therefore, traditional Chinese medicines (TCM) have been accepted as a complementary therapy for knee O.A. For example, acupuncture and Tai Chi are non-surgical treatment options for knee O.A. Additionally, non-pharmacological treatment options to treat knee O.A. in China emphasize a multidisciplinary approach to reduce pain and disability among the Chinese population. Non-pharmacological options include patient education, occupational and physical therapy, aerobic exercises, social support, and weight loss. Also, knee O.A. among the Chinese population is treated by pharmacological therapies such as simple and opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), including COX-2 selective inhibitors, and injectable agents such as glucocorticoids and hyaluronan preparations. Therefore, the rising prevalence of knee O.A. among the aging Chinese population accelerates demand for innovative therapy options, dominating the market growth during the 2022-2030.

Asia Pacific Osteoarthritis Therapy Market Revenue and Forecast to 2030 (US$ Million)

Get more information on this report

Asia Pacific Osteoarthritis Therapy Strategic Insights

Strategic insights for the Asia Pacific Osteoarthritis Therapy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

strategic-framework/asia-pacific-osteoarthritis-therapy-market-strategic-framework.webp

Get more information on this report

Asia Pacific Osteoarthritis Therapy Report Scope

Report Attribute	Details
Market size in 2022	US$ 3,707.81 Million
Market Size by 2030	US$ 7,037.00 Million
Global CAGR (2022 - 2030)	8.3%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Therapy Type Transcutaneous Electrical Nerve Stimulation Occupational Therapy Physical Therapy Platelet-Rich Plasma Therapy & Stromal Vascular Fraction Prolotherapy By Disease Indication Knee Osteoarthritis Spine Osteoarthritis Foot & Ankle Osteoarthritis Shoulder Osteoarthritis Hand Osteoarthritis
Regions and Countries Covered	Asia-Pacific China India Japan Australia Rest of Asia-Pacific
Market leaders and key company profiles	Zimmer Biomet Holdings Inc DePuy Synthes Inc Bioventus Inc Omron Healthcare Inc Exactech Inc Medi GmbH & Co KG Zealmax Innovations Pvt Ltd

Get more information on this report

Asia Pacific Osteoarthritis Therapy Regional Insights

The geographic scope of the Asia Pacific Osteoarthritis Therapy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

geography/asia-pacific-osteoarthritis-therapy-market-geography.webp

Get more information on this report

Asia Pacific Osteoarthritis Therapy Market Segmentation

The Asia Pacific osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.

Based on therapy type, the Asia Pacific osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.

In terms of disease indications, the Asia Pacific osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of Asia Pacific osteoarthritis therapy market in 2022.

Based on end user, the Asia Pacific osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of Asia Pacific osteoarthritis therapy market in 2022.

By country, the Asia Pacific osteoarthritis therapy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific osteoarthritis therapy market share in 2022.

Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, Medi GmbH & Co KG, and Zealmax Innovations Pvt Ltd are some of the leading companies operating in the Asia Pacific osteoarthritis therapy market.

Identical Market Reports with other Region/Countries